Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | GALR3 | O60755 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | ERN1 | O75460 | 8/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473937 | 1.00 | MEN1 (0.72) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| SCHEMBL3236587 | 0.84 | MEN1 (1.00) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| SCHEMBL12492120 | 0.82 | ERN1 (0.69) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| SCHEMBL28075565 | 0.82 | HTT (0.54) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| SCHEMBL2618846 | 0.82 | MEN1 (0.54) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| SCHEMBL19130787 | 0.80 | MEN1 (0.82) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| SCHEMBL13071682 | 0.78 | ERN1 (0.52) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| Dinoterb SCHEMBL53794 | 0.78 | KMT2A (0.79) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| Dinoterb SCHEMBL29487271 | 0.78 | KMT2A (0.79) | MEN1KMT2AHTTGALR3SMN1; SMN2 | |
| Dinoterb SCHEMBL8535102 | 0.78 | KMT2A (0.79) | MEN1KMT2AHTTGALR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111646985-A | Synthetic method of pyrimidine heterocyclic antitumor drug molecule AZD6738 | 江苏集萃分子工程研究院有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-9850223-B2 | Metal catalysts for selective formation of cyclic carbonates, process for preparing cyclic carbonate using the same and use of cyclic carbonate | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-12-26 | — | — | US | disclosed |
| US-20170081302-A1 | METAL CATALYSTS FOR SELECTIVE FORMATION OF CYCLIC CARBONATES, PROCESS FOR PREPARING CYCLIC CARBONATE USING THE SAME AND USE OF CYCLIC CARBONATE | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2017-03-23 | — | — | US | disclosed |
| EP-1213293-B1 | Use of chiral, uncharged metal compounds as doting agents for liquid crystals | BASF AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6713435-B2 | SUCH AS B-PHENYL-GAMMA-BUTYLOLACTONE VIA OXIDATION OF CYCLIC KETONE (3-PHENYLCYCLOBUTANONE) WITH HYDROGEN PEROXIDE/UREA HYDROGEN PEROXIDE IN PRESENCE OF COBALT/SALEN COMPLEX AS CATALYST | KYUSHU UNIVERSITY (JP) | 2004-03-30 | — | — | US | disclosed |
| US-6695977-B2 | LIQUID CRYSTALLINE MIXTURE | BASF AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | disclosed |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | KYUSHU UNIVERSITY (JP) | 2003-06-26 | — | — | US | disclosed |
| US-20030066984-A1 | Use of chiral, uncharged metal compounds as dopants for liquid-crystalline materials | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1288210-A2 | A method for producing optically active lactone compounds by using salen cobalt complexes having a CIS-Beta structure | KYUSHU UNIVERSITY (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1213293-A1 | Use of chiral, uncharged metal compounds as doting agents for liquid crystals | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081302-A1 | METAL CATALYSTS FOR SELECTIVE FORMATION OF CYCLIC CARBONATES, PROCESS FOR PREPARING CYCLIC CARBONATE USING THE SAME AND USE OF CYCLIC CARBONATE | CA2, TMCO1, CA1 | MEN1 228/4885KMT2A 2662/4885HTT 4850/4885 |
| US-20030120091-A1 | Method for producing optically active lactone compounds by using salen cobalt complexes having a cis-beta structure | SOD1, OAT, SOD3 | MEN1 678/4885KMT2A 2629/4885HTT 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.